Amgen vs Cisco: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Cisco was founded in 1984 by Leonard Bosack, Sandy Lerner and is led by Chuck Robbins.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Cisco
Leonard Bosack
Cisco Systems possesses one of the most famous, romanticized, and ultimately contentious founding stories in the history of Silicon Valley. The company was founded in 1984 by a husband-and-wife team, Leonard Bosack and Sandy Lerner.
Sandy Lerner
Sandy Lerner co-founded Cisco Systems in December 1984 with her then-husband Leonard Bosack, driven by the practical need to connect Stanford University's incompatible computer networks.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Cisco
- John Morgridge1988–1995
Former CEO and Chairman
Morgridge was Cisco's first professional CEO, recruited in 1988 by Sequoia Capital investor Don Valentine to professionalize a company still run by its engineering founders.
Source - John Chambers1995–2015
Former Chairman and CEO
Chambers led Cisco for 20 years and transformed it through over 180 acquisitions into the dominant force in enterprise networking infrastructure.
Source - Chuck Robbins2015–present
Chairman and CEO
Robbins has led Cisco's fundamental shift from hardware networking products toward recurring software and subscription revenue. The 28 billion dollar Splunk acquisition in 2024 positioned Cisco as a leading security and observability platform vendor.
Source
Timeline: Amgen and Cisco side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1984Cisco
Company Founded at Stanford University
Leonard Bosack and Sandy Lerner incorporate Cisco Systems in December 1984, commercializing multi-protocol router technology developed to connect Stanford's campus networks.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1986Cisco
First Commercial Router Shipped
Cisco ships its first commercial multi-protocol router, the AGS (Advanced Gateway Server), generating $1.5 million in first-year revenue as the internet begins its transition from research network to commercial infrastructure.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1990Cisco
Initial Public Offering on NASDAQ
Cisco goes public at a valuation of approximately $224 million, raising capital that would fuel its aggressive acquisition strategy. The IPO also precipitated the departure of both founders.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1995Cisco
John Chambers Becomes CEO
John Chambers takes over as CEO from John Morgridge, beginning a 20-year tenure that would see Cisco grow from $2 billion to over $47 billion in annual revenue through more than 180 acquisitions.
2000Cisco
Briefly Becomes World's Most Valuable Company
Cisco's market capitalization exceeds $500 billion in March 2000, briefly surpassing Microsoft and GE as the world's most valuable company before the dot-com crash erased over $400 billion in shareholder value.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2003Cisco
Acquisition of Linksys
Cisco acquires consumer networking company Linksys for $500 million, marking its entry into the home networking market and establishing a consumer brand that would later be divested to Belkin in 2013.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2012Cisco
Meraki Acquisition Launches Cloud-Managed Networking
Cisco acquires cloud-managed networking startup Meraki for $1.2 billion, gaining the platform that would become central to its small-and-medium business strategy and its broader shift toward subscription-based management.
2015Cisco
Chuck Robbins Appointed CEO
Chuck Robbins succeeds John Chambers as CEO, inheriting a mandate to transform Cisco from a hardware company into a software-and-subscription platform business capable of competing in the cloud era.
2017Cisco
AppDynamics Acquisition for $3.7 Billion
Cisco acquires application performance monitoring company AppDynamics for $3.7 billion just days before its planned IPO, signaling Cisco's strategic commitment to the observability and application intelligence market.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020Cisco
Webex Usage Surges During COVID-19 Pandemic
Webex usage explodes to over 600 million meeting participants per month during the pandemic, temporarily positioning Cisco's collaboration platform as a critical piece of global remote work infrastructure.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024Cisco
$28 Billion Splunk Acquisition Completed
Cisco completes its largest-ever acquisition, purchasing cybersecurity and observability company Splunk for $28 billion in cash, pushing subscription revenue past 51% of total sales and establishing Cisco as a major force in security operations.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Cisco
AI Infrastructure Orders Exceed $2 Billion
Cisco's AI infrastructure orders from hyperscale customers surpass $2 billion in FY2025, more than doubling management's original target and validating the company's investment in Silicon One-based networking platforms for GPU cluster interconnection.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs Cisco
Who is the CEO of Amgen Inc. and Cisco Systems, Inc.?
Amgen Inc. is led by Robert A. Bradway and Cisco Systems, Inc. is led by Chuck Robbins. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Cisco Systems, Inc.?
Amgen Inc. was founded in 1980 — 4 years before Cisco Systems, Inc., which was founded in 1984. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Cisco Systems, Inc..
How many employees does Amgen Inc. have compared to Cisco Systems, Inc.?
Amgen Inc. employs approximately 31,500 people, while Cisco Systems, Inc. employs approximately 82,400. Cisco Systems, Inc. has the larger workforce at 82,400 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Cisco Systems, Inc. headquartered?
Both Amgen Inc. and Cisco Systems, Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Cisco Systems, Inc.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Cisco Systems, Inc. was founded by Leonard Bosack, Sandy Lerner.
Which company has a longer operating history — Amgen Inc. or Cisco Systems, Inc.?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. Cisco Systems, Inc. has been in operation for around 42 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Cisco overview